Chian et al. reported that luteolin sensitized two oxaliplatin-resistant CRC cell lines (HCT116 and SW620) to chemotherapeutic drugs (oxaliplatin, cisplatin, and doxorubicin) by inhibiting the Nrf2 pathway, which may reduce drug resistance [211]. Here, NFE2L2 is linked to colorectal carcinoma.